WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015116729) ANTI-CD37 ANTIBODY AND ANTI-CD20 ANTIBODY COMBINATION THERAPY FOR TREATMENT OF B-CELL MALIGNANCIES AND DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/116729    International Application No.:    PCT/US2015/013367
Publication Date: 06.08.2015 International Filing Date: 28.01.2015
IPC:
A61K 39/395 (2006.01), C07K 16/00 (2006.01)
Applicants: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC [US/US]; 2401 4th Avenue, Suite 1050 Seattle, Washington 98121 (US)
Inventors: STROMATT, Scott; (US).
GORDON, Brian; (US)
Agent: GETTS, Meghann; (US)
Priority Data:
61/932,518 28.01.2014 US
62/088,179 05.12.2014 US
Title (EN) ANTI-CD37 ANTIBODY AND ANTI-CD20 ANTIBODY COMBINATION THERAPY FOR TREATMENT OF B-CELL MALIGNANCIES AND DISORDERS
(FR) POLYTHÉRAPIE À BASE D'ANTICORPS ANTI-CD37 ET D'ANTICORPS ANTI-CD20 POUR LE TRAITEMENT D'AFFECTIONS MALIGNES ET DE TROUBLES DES LYMPHOCYTES B
Abstract: front page image
(EN)The present invention provides methods of treating a patient with a B-cell malignancy or disorder comprising administering an anti-CD37 antibody or antibody fragment in combination with an anti-CD20 antibody or antibody fragment. In one embodiment, the invention provides methods for B-cell reduction comprising contacting B-cells with an anti-CD37 antibody or antibody fragment and an anti-CD20 antibody or antibody fragment. The invention includes compositions and kits comprising anti-CD37 antibody and antibody fragments for use in combination with an anti-CD20 antibody or antibody fragment. The methods and compositions of the invention may further include a BCR antagonist such as a SYK inhibitor, a BTK inhibitor, a PI3K inhibitor, or a CXCR4 antagonist.
(FR)La présente invention concerne des procédés de traitement d'un patient souffrant d'une affection maligne ou d'un trouble des lymphocytes B comprenant l'administration d'un anticorps, ou fragment d'anticorps, anti-CD37 en combinaison avec un anticorps, ou fragment d'anticorps, anti-CD20. Dans un mode de réalisation, l'invention concerne des procédés de réduction des lymphocytes B comprenant la mise en contact des lymphocytes B avec un anticorps, ou fragment d'anticorps, anti-CD37 et un anticorps, ou fragment d'anticorps, anti-CD20. L'invention concerne des compositions et des kits comprenant des anticorps, et fragments d'anticorps, anti-CD37 pour une utilisation en combinaison avec un anticorps, ou fragment d'anticorps, anti-CD20. Les procédés et les compositions de l'invention peuvent en outre comprendre un antagoniste de BCR tel qu'un inhibiteur de SYK, un inhibiteur de BTK, un inhibiteur de la PI3K, ou un antagoniste de CXCR4.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)